• Explore /
  • Poster
  • / KEYlargo: A phase II study of first-line pembrolizumab (P), capecitabine (C), and oxaliplatin (O) in HER2-negative gastroesophageal (GE) adenocarcinoma.

KEYlargo: A phase II study of first-line pembrolizumab (P), capecitabine (C), and oxaliplatin (O) in HER2-negative gastroesophageal (GE) adenocarcinoma.

Abstract Poster

Authors

null

Hope Elizabeth Uronis

Duke University Medical Center, Durham, NC

Hope Elizabeth Uronis , Christel Rushing , Gerard C. Blobe , Shiaowen David Hsu , Niharika B. Mettu , James Leroy Wells , Donna Niedzwiecki , Leighanne Hartman , Ashley Moyer , Herbert I. Hurwitz , John H. Strickler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03342937

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 228)

DOI

10.1200/JCO.2021.39.3_suppl.228

Abstract #

228

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Lin Shen

First Author: Manish A. Shah

First Author: Yongkun Sun

First Author: Zev A. Wainberg